Acute graft-versus-host disease (aGVHD) is a frequent and major complication after allogeneic stem cell transplantation. For many years psoralen and ultraviolet (UV)-A light have been used in the treatment of chronic cutaneous graft-versus-host disease, but few patients have received PUVA therapy for aGVHD. We assessed 20 patients who received PUVA therapy for acute cutaneous GVHD (grade 2-4). Seven patients showed additional organ manifestations (liver, gut). To better quantify the cutaneous lesions, a new scoring system was introduced: intensity of erythema (0-3) × %body surface + size of bullae (4-5) × %body surface affected. All patients received prednisolone and PUVA for treatment of aGVHD. Fifteen patients (75%), 12 with manifestations restricted to the skin, responded by score classification (average time to a 50% score reduction: 39 days) and reduction of the dosage of prednisolone (average time to a 50% prednisolone reduction: 35 days). PUVA treatment was well tolerated and might play a role in the therapy of acute cutaneous GVHD.
Allogeneic bone marrow transplantation is the only curative treatment for a variety of hematological malignancies. One frequent and major complication of this treatment modality is the occurrence of acute graft-versus-host disease (aGVHD).
Management of acute and chronic GVHD often requires immunosuppressive therapy over a prolonged time period, eg cyclosporin A and prednisolone. Due to immunosuppression, patients have an additional risk of infectious complications associated with increased morbidity and mortality.
One main localization of acute GVHD is the skin, characterized in its mild form by an erythematous morbilliform eruption, and in its extensive form as epidermal necrolysis, developing up to 100 days after allogeneic stem cell transplantation. For many years, 8-methoxypsoralen and ultraviolet-A light have been used in the treatment of a variety of skin diseases, such as psoriasis, cutaneous T cell lymphoma and vitiligo. There are several studies using PUVA therapy in the treatment of chronic cutaneous GVHD, [1] [2] [3] [4] [5] [6] [7] [8] [9] but few patients have received PUVA therapy for treatment of acute cutaneous GVHD. [6] [7] [8] [9] [10] [11] At our institution 20 patients were studied who received PUVA therapy for acute cutaneous GVHD, to evaluate the role of photochemotherapy in the treatment of acute graftversus-host disease.
Patients and methods

Patients
Twenty patients (10 male, 10 female) received PUVA therapy as treatment for acute cutaneous GVHD after allogeneic bone marrow transplantation (nine patients with CML, five AML, two ALL, two MDS, one CLL, one chronic myeloproliferative syndrome). Thirteen patients had undergone allogeneic transplantation from a matched sibling donor and seven from a matched unrelated donor between 1995 and 1997. All patients developed cutaneous acute GVHD; six out of these 20 patients showed additional organ manifestations (liver, gut).
Conditioning regimens
Eleven patients received busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg), and in addition one patient received melphalan (140 mg/m 2 ), and one patient received cytarabine (2 × 1 g/m 2 for 2 consecutive days). Five patients underwent TBI (12 Gy) with cyclophosphamide (120 mg/kg), and in addition one patient received VP-16 (40 mg/kg),and another received thiotepa (10 mg/kg).
Supportive care
Patients were admitted to the hematologic intensive care unit and transferred to a laminar air unit on the day of transplantation. Supportive infusion therapy consisting of parenteral feeding and vitamins was administered through a tunneled Hickman catheter. For antimicrobial prophylaxis, patients received antibiotics (ciprofloxacin, 2 × 500 mg/day), antifungal (fluconazol, 400 mg/day) and antiviral (acyclovir, 4 × 400 mg p.o./day) medication and immunoglobulin infusions (0.25 mg/kg polyvalent immunoglobulin every 3 weeks).
GVHD prophylaxis
All patients received CsA (5 mg/kg/day intravenously for the first 20 days followed by oral medication) from day Ϫ1 until at least day +100; in addition, four patients received a short course of methotrexate (15 mg/m 2 day 1, 10 mg/m 2 day 3 and 6); one patient received prednisolone (1 mg/kg/day) from day +3 and five patients received antithymocyte globulin (ATG Fresenius, 20 mg/kg day Ϫ4 to day Ϫ2).
GVHD staging
Clinical staging of acute GVHD was performed as described previously. 12 In two patients, cutaneous GVHD was confirmed by histopathology of the skin and in three patients by histopathology of intestinal and/or liver biopsy. In addition, autopsy confirmed acute GVHD in another three patients.
To better quantify the cutaneous lesions prior to PUVA therapy and thus to better assess local control of acute GVHD, a new scoring system was introduced. Extent of cutaneous manifestations of aGVHD was quantified by: intensity of erythema (0, no erythema; 1, slight erythema; 2, clearly noticable erythema; 3, marked erythema) × %body surface + size of bullae (0, no bullae; 4, small bullae; 5, big bullae) × %body surface affected.
GVHD therapy
For initial therapy of acute GVHD, all patients received prednisolone (2 mg/kg). In patients with progression of cutaneous GVHD after 3 days of standard dose prednisolone (2-5 mg/kg) additional PUVA therapy was initiated. Two hours after oral administration of 8-methoxypsoralen (0.6 mg/kg), UVA treatment was started and given four times/week. The initial dose varied between 0.3 and 0.5 J/cm 2 . According to the response of cutaneous lesions, the dose was subsequently increased by 0.5 J/cm 2 increments to a maximal dose of 8.0 J/cm 2 . After resolution of cutaneous symptoms and cessation of prednisolone treatment, PUVA therapy was administered twice a week for another 4 weeks until discontinuation. Patients not responding to PUVA and prednisolone therapy (2-5 mg/kg) received increasing doses of steroids (10 mg/kg-20 mg/kg). Non-responders to high-dose steroid therapy treatment received OKT3 therapy (5 mg/day for 10 days).
Results
Twenty patients with acute cutaneous GVHD were treated with PUVA therapy. GVHD was diagnosed by typical clinical manifestations, and additionally, by histopathological analysis in eight patients. Demographic data are shown in Table 1 . Fourteen patients developed acute GVHD grade II, five patients grade III and one patient grade IV. Six out of 20 patients showed involvement of the liver and gut by acute GVHD.
Two patients with rapid progression of acute GVHD when receiving high dose corticosteroid treatment (20 mg/kg) were treated with OKT3 therapy. One patient with an initial response to corticosteroids (2 mg/kg) plus PUVA therapy had a severe relapse of cutaneous acute GVHD when PUVA was stopped. This patient refused further PUVA therapy and was treated with FK 506.
To better quantify the skin lesions, they were assessed by a new scoring system. The mean score at the beginning of PUVA therapy was 168 (range, 30-388). The mean maximal dose of prednisolone for treatment of acute GVHD was 8 mg/kg/day (range, 2-20 mg/kg/day).
PUVA therapy was well tolerated, with only two patients developing erythema following UV-A light exposure. Irradiation data are shown in Table 2 .
Fifteen of 20 patients (75%) responded by score classification, clinical GVHD staging, and prednisolone reduction. The response rate was 92% (12/13 patients) in patients with acute GVHD confined to the skin. In contrast, only 33% of the patients (2/6) with additional organ manifestations (liver/gut) showed a response to PUVA therapy and prednisolone. The average time to a 50% prednisolone reduction was 35 days (range, 5-133 days). The average time to a 50% reduction according to the scoring system described above was 39 days (range, 10-86 days; Table 3 ). Nine of 20 patients died of relapse, infectious complications, or progression of hepatic or intestinal acute GVHD.
Discussion
For many years psoralen and UV-A light have been used in the treatment of chronic cutaneous GVHD after allogeneic transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Few patients have received PUVA therapy for acute cutaneous GVHD. [6] [7] [8] [9] [10] [11] Furthermore, there are few reports of successful treatment of acute GVHD with extracorporal photopheresis. 13, 14 At our institution, 20 patients with acute cutaneous GVHD after allogeneic stem cell transplantation were treated with PUVA therapy in an uncontrolled and unmatched study, with a response rate of 76%.
Acute GVHD is considered as a multi-step process that consists of an initial afferent phase (antigen recognition and T cell activation), followed by an amplification phase (clonal proliferation/differentiation and cytokine release) resulting in an efferent phase of tissue damage. 15, 16 Transplant conditioning regimens cause tissue damage (e.g. intestinal mucosa), leading to release of inflammatory cytokines such as TNF-alpha and Il-1 by activated host cells. It has been shown that an increase of the TBI dose or high TNFalpha levels during conditioning is associated with an increased risk of GVHD development and mortality. 17, 18 Secretion of inflammatory cytokines may upregulate MHC antigens and further facilitate host recognition by donor T cells. T cell activation results in a proliferation of Th1 T cells with secretion of IL-2 and IFN-gamma, which induce further T cell expansion, cytotoxic T cell and natural killer cell response, resulting in the effector phase of target organ damage.
Although the exact mechanism of PUVA therapy remains unclear, there are in vivo and in vitro data which show immunological effects that might influence the cascade of events and the cytokine dysregulation during the development of acute GVHD. Several experimental models have been used to examine the influence of PUVA therapy on lymphocyte function. Perez et al 19 have shown that infusion of PUVA-treated splenocytes from BALB/c mice grafted with CBA/J mouse skin into syngeneic mice induces tolerance to CBA/J major histocompatibility complex (MHC) antigens. Recipients were unresponsive in mixed lymphocyte reactions and cytotoxicity assays. In addition, they had no delayed-type hypersensivity against CBA/J cells, and rejection of CBA/J skin graft was delayed. 19 Laskin and co-workers 20 found that PUVA treatment of mouse T cells induces inhibition of mitogen-induced, as well as antigen-specific T cell proliferation. Bredberg and Forsgren 21 showed inhibition of chemotaxis of leukocytes following PUVA treatment.
Furthermore, modulation of the cytokine network following PUVA treatment has been documented in animal studies, as well as in cell culture. Aubin et al 22 reported that the activation of mouse keratinocytes with psoralen and UV-A irradiation induced the release of a soluble factor depressing alloreactivity. In a mouse model, Okamoto et al 23 showed markedly suppressed production of IL-2 on day 3 with normalization of serum levels not before day 7 postirradiation. Rivas and co-workers 24 demonstrated that exposure of murine keratinocyte cultures to UV irradiation caused a systemic suppression of delayed-type hypersensitivity by release of IL-10. Several studies show a marked influence of PUVA therapy on Langerhans cells, not only by a reduction of the cell number, but by a down-modulation of antigen-presenting function and a reduction of cytokine release. [25] [26] [27] [28] [29] [30] UV-B light exposure has been reported to convert Langerhans cells from immunogenic to tolerogenic antigen-presenting cells, defective in their autocrine Il-2 production. 30 Due to PUVA induced reduction of the number of Langerhans cells in the skin, the alteration of their antigenpresenting function and the modulation of cytokine secretion, PUVA therapy might be effective not only in chronic, but also in acute GVHD.
154
As documented by clinical improvement, GVHD score, and reduction in the dose of steroids administered, 92% of our patients with acute cutaneous GVHD responded to PUVA therapy. In all but two patients with additional organ manifestations of acute GVHD, no significant response and thus no reduction of the dose of corticosteroids could be achieved. Thus, in our opinion PUVA therapy should be restricted to patients with predominantly cutaneous manifestations of acute GVHD.
The newly established scoring system allows a better assessment of cutaneous GVHD and its response to therapy. PUVA therapy was well tolerated and effective in 92% of patients with acute cutaneous GVHD. No late complications, such as cutaneous squamous cell carcinoma or severe hyperlipidemia 31, 32 were observed in our patients, but the brief follow-up period does not allow firm conclusions.
No severe side-effects occurred during or following PUVA treatment.
Clearly, randomised prospective studies are warranted and are now underway to further assess the value of PUVA therapy for acute cutaneous GVHD.
